- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Do | ASX Quarterly Health Wrap: Bioxyne revenue up 77%, Radiopharm lists on Nasdaq | 2 | Stockhead | ||
| Do | RADIOPHARM THERANOSTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | 1 | ASX | ||
| 23.01. | RADIOPHARM THERANOSTICS LIMITED: Change in substantial holding | - | ASX | ||
| 22.01. | RADIOPHARM THERANOSTICS LIMITED: Change in substantial holding | 1 | ASX | ||
| 21.01. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 21.01. | RADIOPHARM THERANOSTICS LIMITED: Notice Under Section 708A | 1 | ASX | ||
| 21.01. | RADIOPHARM THERANOSTICS LIMITED: Application for quotation of securities - RAD | 1 | ASX | ||
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| 20.01. | Dr Boreham's Crucible: Radiopharm hopes to turn up the sweet sound of success | 6 | Stockhead | ||
| 20.01. | RADIOPHARM THERANOSTICS LIMITED: Response to ASX Cleansing Notice Validity Letter | - | ASX | ||
| 10.01. | Lantheus increases to 12.16% shareholding in Radiopharm Theranostics | 2 | Seeking Alpha | ||
| 10.01. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.01. | Health Check: Radiopharm dials up after gaining new major shareholder | 1 | Stockhead | ||
| 10.01. | $8M deal sees Private Lantheus pick up 12.16% of Radiopharm Theranostics | 4 | The Market Herald Australia | ||
| 08.01. | RADIOPHARM THERANOSTICS LIMITED: Lantheus increases shareholding in RAD with A$8m placement | - | ASX | ||
| 30.12.24 | Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday | 16 | Benzinga.com | ||
| 30.12.24 | Radiopharm Theranostics: Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia | 251 | GlobeNewswire (Europe) | RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging trialFinancial incentives to be paid to RAD upon... ► Artikel lesen | |
| 30.12.24 | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 29.12.24 | RADIOPHARM THERANOSTICS LIMITED: Strategic Co-Development Partnership with Lantheus for Aus | - | ASX | ||
| 20.12.24 | Radiopharm Theranostics: RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial | 221 | GlobeNewswire (Europe) | Ethics approval received in Australia for the initiation of RAD's Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric CancersThe Phase 1 First-In-Human study is designed to assess the... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
92 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 61,86 | 0,00 % | Tempus AI-Aktien steigen vorbörslich um 5% dank anhaltender Dynamik und Übernahme von Ambry Genetics | ||
| IMMUNOVANT | 20,910 | +0,53 % | Here's Why Immunovant, Inc. (IMVT) Will Double in 2025 | ||
| SPRINGWORKS THERAPEUTICS | 38,400 | +7,20 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025 | ||
| ADMA BIOLOGICS | 16,900 | +2,61 % | Engaging In Insider Activity, Kaitlin M. Kestenberg-Messina At ADMA Biologics Exercises Options Worth $28K | ||
| AVIDITY BIOSCIENCES | 33,340 | +4,35 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen | |
| JANUX THERAPEUTICS | 41,310 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 38,980 | +0,72 % | Harmony Biosciences Stock Scores 80-Plus RS Rating | ||
| 89BIO | 10,750 | 0,00 % | Hedge Fund and Insider Trading News: Ken Griffin, Paul Singer, Greenlight Capital, Balyasny Asset Management, Ashland Inc (ASH), 89bio Inc (ETNB), and More | ||
| DYNE THERAPEUTICS | 14,790 | +6,63 % | Dyne's Myotonic Secures FDA's Fast Track Designation For Myotonic Dystrophy Type 1 Therapy | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN), Tuesday announced that the U.S. Food and Drug Administration has granted Fast Track designation for DYNE-101 for the treatment of myotonic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,610 | 0,00 % | How Is The Market Feeling About Recursion Pharmaceuticals? | ||
| BEAM THERAPEUTICS | 25,750 | +0,63 % | (BEAM) - Analyzing Beam Therapeutics' Short Interest | ||
| EDGEWISE THERAPEUTICS | 29,500 | +4,54 % | Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024... ► Artikel lesen | |
| ARVINAS | 18,050 | 0,00 % | Arvinas stock plunges to 52-week low at $16.95 amid market challenges | ||
| ARCUTIS BIOTHERAPEUTICS | 13,100 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million | Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. Q3 2024Preliminary unaudited product... ► Artikel lesen |
Das Unternehmen RADIOPHARM THERANOSTICS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,360 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.
